These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23340175)

  • 1. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
    Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.
    Seo JH; Jung KH; Son MK; Yan HH; Ryu YL; Kim J; Lee JK; Hong S; Hong SS
    Cancer Lett; 2013 Sep; 338(2):271-81. PubMed ID: 23587795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.
    Lee H; Jung KH; Jeong Y; Hong S; Hong SS
    Cancer Lett; 2013 Jan; 328(1):152-9. PubMed ID: 22929971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
    Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
    Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
    Ryu YL; Jung KH; Son MK; Yan HH; Kim SJ; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Oct; 353(1):68-77. PubMed ID: 25016056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
    Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
    Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.
    Li GY; Jung KH; Lee H; Son MK; Seo J; Hong SW; Jeong Y; Hong S; Hong SS
    Cancer Lett; 2013 Feb; 329(1):59-67. PubMed ID: 23085493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
    Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
    Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
    Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
    Chu JH; Zhao CR; Song ZY; Wang RQ; Qin YZ; Li WB; Qu XJ
    Biomed Pharmacother; 2014 Apr; 68(3):335-41. PubMed ID: 24581722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
    Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
    Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
    Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
    Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W; Adachi M; Zhang R; Zhou J; Zhu D
    Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
    Pennarun B; Kleibeuker JH; Boersma-van Ek W; Kruyt FA; Hollema H; de Vries EG; de Jong S
    J Pathol; 2013 Feb; 229(3):410-21. PubMed ID: 23132258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.